Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world iruplinalkib in ALK-positive advanced or metastatic NSCLC
ChiCTR2400087055Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iruplinalkib in ALK-positive non-small cell lung cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Safety. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
iruplinalkib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2400087055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087055.